CDTI

Atani Defies the Crypto Winter and Secures $6M in Funding for Its New Broker

Retrieved on: 
Thursday, October 26, 2023
Crypto, SoftBank Group, Organizational founder, Bank, JME, Fintech, Acronicta, Bank of Spain, Growth, CDTI, Ecosystem, CPO, Security (finance), Cryptocurrency

Spain-based crypto fintech startup Atani , is announcing the successful completion of a funding round of $6 million.

Key Points: 
  • Spain-based crypto fintech startup Atani , is announcing the successful completion of a funding round of $6 million.
  • Trusted by over 300,000 traders around the globe, Atani is the crypto broker where any crypto asset can be found and traded.
  • The crypto ecosystem was missing an experience similar to that of digital stock brokers” said Paul Barroso , Co-founder & CPO of Atani.
  • “We founded Atani back in 2019 driven by a long-term vision of making investing in crypto markets simple, efficient, and secure.

inari raises $5.2 Million Seed Round to Transform Insurance Infrastructure Market

Retrieved on: 
Friday, September 8, 2023
Insurance, Professional Services, Policy, API, Risk management, Véronique, Creativity, MGA, CDTI, Risk, CaixaBank, ANV, HCC, Geography, Financial services, Management

Inari, a core technology infrastructure provider for the global insurance and reinsurance industry, has raised $5.2 million in funding as part of their Seed round led by Caixa Capital Risc, through Criteria Venture Tech.

Key Points: 
  • Inari, a core technology infrastructure provider for the global insurance and reinsurance industry, has raised $5.2 million in funding as part of their Seed round led by Caixa Capital Risc, through Criteria Venture Tech.
  • Founded in 2017, inari helps its clients operate as next generation insurance and reinsurance organizations both for greenfield operations and long-established companies.
  • The inari client base is worldwide in geography and includes MGAs, Insurance Carriers, Lloyd’s Syndicates and Reinsurance companies in Europe, the Lloyd’s and London markets, US, Asia and Bermuda.
  • Inari provides core insurance policy administration, underwriting dashboard and bordereaux management systems for MGAs, Insurance Carriers, Lloyd’s Syndicates and Reinsurance companies worldwide.

Bombardier Introduces Advanced Avionics Upgrade for In-Service Global Aircraft Equipped with the Bombardier Vision Flight Deck

Retrieved on: 
Wednesday, August 30, 2023
EFIS, SVS, Bombardier Global Express, Synthetic vision system, Electronic flight instrument system, EICAS, CVS, Business, Challenger, EVS, HUD, Lockheed Martin X-59 QueSST, Report, Learjet, Radar, CDTI, Logic, MRT, PFD, Weather, Collins Aerospace, Safety, AAU, GameChanger, Airline, Instrumentation, Bombardier

New upgrade enhances situational awareness and essential visualization features, boosts safety and efficiency

Key Points: 
  • New upgrade enhances situational awareness and essential visualization features, boosts safety and efficiency
    Available for Bombardier Vision flight deck of in-service Global 5000, Global 6000, Global 5500 and Global 6500 aircraft, leveraging features introduced on in-production Global 5500 and Global 6500 aircraft
    A Global 6000 business jet is the first aircraft to receive the upgrade, which is available now at all Bombardier service centres worldwide
    MONTRÉAL, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bombardier today introduced its new Advanced Avionics Upgrade (AAU) for the Bombardier Vision flight deck, a new avionics software and hardware enhancement that boasts the latest technology to enhance situational awareness and offer advanced visualization features.
  • Powered by Collins Aerospace and available for in-service Global 5000, Global 6000, Global 5500 and Global 6500 aircraft equipped with the Bombardier Vision flight deck, the AAU is designed to take in-service Global aircraft to the next level by providing avionics features currently available on in-production Global 5500 and Global 6500 aircraft.
  • A Global 6000 business jet is the first aircraft to receive the upgrade, which is currently being installed at the Wichita Service Centre.
  • Installation of the AAU on in-service Global aircraft is available across the complete Bombardier service centre network.

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)

Retrieved on: 
Wednesday, May 3, 2023
European Innovation Council, MBNL, Industrial technology, Venture round, CSO, DM1, MicroRNA, Myotonic dystrophy, Muscle weakness, Development, Centre for the Development of Industrial Technology, CDTI, Patient, Growth, EIC, Disease, Pharmaceutical industry

VALENCIA, Spain, May 3, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs announced the closing of its €42 million Series B financing round led by Columbus Venture Partners, with participation from new investors, the European Innovation Council (EIC), Hadean Ventures, and Sound Bioventures. Existing investors Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI) through its Innvierte program, also participated in the financing. 

Key Points: 
  • Existing investors Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI) through its Innvierte program, also participated in the financing.
  • The Series B proceeds will be used to advance its lead compound, ATX-01, an antimiR designed to target microRNA 23b (miR-23b), to a Phase I/IIa clinical trial for the treatment of Myotonic Dystrophy Type 1 (DM1).
  • There are currently no disease-modifying treatments for DM1, which affects at least 40,000 people in the U.S and 70,000 in Europe.
  • In connection with the financing, ARTHEx' present Chairman of the Board of Directors, Dr. Frédéric Legros, has been appointed Chief Executive Officer.

Destinus Awarded Grants from Spanish Government for Hydrogen Flight

Retrieved on: 
Thursday, March 23, 2023
PTA, Hydrogen, European Commission Investment Plan for Europe, Research, CDTI, European Commission, Management, Lithium, EU

MADRID, Spain and PAYERNE, Switzerland, March 23, 2023 /PRNewswire-PRWeb/ -- Destinus (http://www.destinus.com), a European aerospace firm specializing in high-speed hydrogen-powered airplanes, has been chosen by the Spanish Ministry of Science's Centro para el Desarrollo Tecnológico e Industrial (CDTI) program to participate in a strategic initiative, and awarded grants to further R&D for supersonic flight utilizing hydrogen as fuel. The project has an overall investment of €12 million and involves companies and technology centres, as well as Spanish universities.

Key Points: 
  • The project has an overall investment of €12 million and involves companies and technology centres, as well as Spanish universities.
  • The grant funds the construction of a test facility near Madrid for air-breathing hydrogen engines which Destinus will help design and iterate through further testing.
  • The Spanish government invests heavily in developing hydrogen propulsion as part of its economic resilience and transformation plan through strategic projects funded by the European Commission's Next Gen funds.
  • "We are delighted to have been awarded these grants, especially because they are a clear sign that Destinus is aligned with the strategic lines of Spain and Europe to advance hydrogen flight," said Davide Bonetti, VP Business Development and Products for Destinus.

Tribaldata, which is helping the advertising industry get to Net Zero, has completed its seed round for 0,8M eur.

Retrieved on: 
Wednesday, January 11, 2023
CDTI, Advertising, Microsoft, Sustainable Development Goals, Sustainable Development Goal 13, Society, Growth, Climate change, Carbon, Xandr, First Nations in Ontario, United Nations, Renewable energy, Recycling

The global advertising industry responded by coming together last July around the Ad Net Zero program with the task of reducing emissions along the entire advertising value chain and charting the path to net zero emissions by 2030.

Key Points: 
  • The global advertising industry responded by coming together last July around the Ad Net Zero program with the task of reducing emissions along the entire advertising value chain and charting the path to net zero emissions by 2030.
  • Supporting this effort, Tribaldata is helping media agencies, advertisers and publishers accelerate in getting to Net Zero, through a combination of services around unique consumer insight and data on consumers, direct campaign emission offsetting and access to usage of their platform.
  • Last year the company also partnered with Xandr, a Microsoft Company that operated one of the largest global premium advertising marketplaces.
  • This adds to the 250k eur Neotec subsidy received by Tribaldata early 2022 from Spanish public entity CDTI.

The 2nd annual Connecting Green Hydrogen Europe 2023 will Take Place in Madrid, Spain

Retrieved on: 
Tuesday, January 10, 2023
Hydrogen, Hive, CDTI, Multimedia, IPP, ENGIE, European Commission, Engineering, Shell, Centre for the Development of Industrial Technology, Demography, International Renewable Energy Agency, Royal commission, Enel Green Power, Exhibition, Development, PRF, CNH2, Air Liquide, BASF, World Steel Association, CGHE, Hotel Riu Plaza Guadalajara, Union of International Mountain Leader Associations, RHI Magnesita, EWE, Associate, Ministry (collective executive), INEOS, PGNiG, Oil, Industrial technology, Ministry of the Ecological Transition (France), OMV, App Store (iOS/iPadOS), EDP Renováveis, Gas, E.ON, Naturgy, IRENA, European Association of Bodies and Public Organizations of Security and Defense, Renewable energy, Woman, Aperam, BP

MADRID, Jan. 10, 2023 /PRNewswire/ -- Connecting Green Hydrogen Europe (CGHE2023) 2023 – Advancing Towards Europe's Green Hydrogen Roadmap – is taking place on 5th – 6th July 2023 at Riu Plaza España Madrid, Spain.

Key Points: 
  • MADRID, Jan. 10, 2023 /PRNewswire/ -- Connecting Green Hydrogen Europe (CGHE2023) 2023 – Advancing Towards Europe's Green Hydrogen Roadmap – is taking place on 5th – 6th July 2023 at Riu Plaza España Madrid, Spain.
  • As a region's high-end conference & exhibition toward a green hydrogen future in Europe, Connecting Green Hydrogen Europe 2023 will bring together the entire hydrogen value chain to focus on developing solutions and innovations for low-carbon hydrogen production, efficient storage and distribution, and applications in various stationary and mobile applications in Europe.
  • CGHE2023 creates a tailored setting where senior decision-makers could network, share pragmatic approaches supporting the green hydrogen growth, and green hydrogen industry hub in Europe, foster international partnerships to facilitate green hydrogen economics.
  • As the premier event focusing on the hydrogen industry, Connecting Green Hydrogen Europe has been held successfully in Madrid for two consecutive years.

The 2nd annual Connecting Green Hydrogen Europe 2023 will Take Place in Madrid, Spain

Retrieved on: 
Tuesday, January 10, 2023
Hydrogen, Hive, Shell, CDTI, Hotel Riu Plaza Guadalajara, Union of International Mountain Leader Associations, Centre for the Development of Industrial Technology, Demography, RHI Magnesita, PGNiG, Oil, International Renewable Energy Agency, Industrial technology, Ministry of the Ecological Transition (France), OMV, App Store (iOS/iPadOS), Royal commission, EDP Renováveis, European Association of Bodies and Public Organizations of Security and Defense, IPP, EWE, Enel Green Power, Exhibition, ENGIE, Development, PRF, Associate, Gas, CNH2, European Commission, Ministry (collective executive), Air Liquide, BASF, INEOS, Engineering, E.ON, Naturgy, IRENA, World Steel Association, CGHE, Renewable energy, BP, Woman, Aperam

MADRID, Jan. 10, 2023 /PRNewswire/ -- Connecting Green Hydrogen Europe (CGHE2023) 2023 – Advancing Towards Europe's Green Hydrogen Roadmap – is taking place on 5th – 6th July 2023 at Riu Plaza España Madrid, Spain.

Key Points: 
  • MADRID, Jan. 10, 2023 /PRNewswire/ -- Connecting Green Hydrogen Europe (CGHE2023) 2023 – Advancing Towards Europe's Green Hydrogen Roadmap – is taking place on 5th – 6th July 2023 at Riu Plaza España Madrid, Spain.
  • As a region's high-end conference & exhibition toward a green hydrogen future in Europe, Connecting Green Hydrogen Europe 2023 will bring together the entire hydrogen value chain to focus on developing solutions and innovations for low-carbon hydrogen production, efficient storage and distribution, and applications in various stationary and mobile applications in Europe.
  • CGHE2023 creates a tailored setting where senior decision-makers could network, share pragmatic approaches supporting the green hydrogen growth, and green hydrogen industry hub in Europe, foster international partnerships to facilitate green hydrogen economics.
  • As the premier event focusing on the hydrogen industry, Connecting Green Hydrogen Europe has been held successfully in Madrid for two consecutive years.

Arthex announces regulatory milestones met in its program to develop ATX-01 in Myotonic Dystrophy Type 1

Retrieved on: 
Wednesday, December 14, 2022
Chemistry, DM1, Industrial technology, Drug discovery, Scientific Advice Mechanism, Development, Food, IND, Muscle, EMA, Toxicology, Patient, Orphan drug, Myotonic dystrophy, Disease, FDA, Fatigue, CMC, CTA, MicroRNA, ODD, European Medicines Agency, Hypersomnia, Science, CDTI, Tissue, Food and Drug Administration Amendments Act of 2007, FIH, Centre for the Development of Industrial Technology, Pharmaceutical industry

Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.

Key Points: 
  • Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.
  • Myotonic dystrophy type 1 (DM1) is a highly disabling disease affecting more than one million people worldwide.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.
  • Arthex Biotech's investors are Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI).

Arthex announces regulatory milestones met in its program to develop ATX-01 in Myotonic Dystrophy Type 1

Retrieved on: 
Wednesday, December 14, 2022
Chemistry, DM1, Industrial technology, Drug discovery, Scientific Advice Mechanism, Development, Food, IND, Muscle, EMA, Toxicology, Patient, Orphan drug, Myotonic dystrophy, Disease, FDA, Fatigue, CMC, CTA, MicroRNA, ODD, European Medicines Agency, Hypersomnia, Science, CDTI, Tissue, Food and Drug Administration Amendments Act of 2007, FIH, Centre for the Development of Industrial Technology, Pharmaceutical industry

Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.

Key Points: 
  • Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.
  • Myotonic dystrophy type 1 (DM1) is a highly disabling disease affecting more than one million people worldwide.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.
  • Arthex Biotech's investors are Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI).